pressed in more than 70% of gastric carcinoma. The overexpression is associated with *p53* mutations. Therefore, Chk1 and Chk2 may play a role in checkpoint function in gastric carcinoma harboring *p53* mutation when their functions are preserved to prevent cell-cycle progression.

Angiogenic Factors

Angiogenesis, which is a prerequisite for tumor growth and metastasis, depends on the production of angiogenic factors by host and tumor cells (Fig. 2). Increased vascularity enhances the growth of primary neoplasms and provides an avenue for hematogenous metastasis. In gastric carcinoma, increasing microvessel counts correlate with lymph node metastasis, hepatic metastasis, and poor prognosis. Several growth factors have been identified that regulate angiogenesis in gastric carcinoma [4]. Gastric carcinoma cells produce various angiogenic factors, including vascular endothelial growth factor (VEGF), interleukin (IL)-8, basic fibroblast growth factor (bFGF), and platelet-derived endothelial cell growth factor (PD-ECGF) [4,16–18]. Takahashi et al. [16] have found that the angiogenic phenotype differs between the well-differentiated type and poorly differentiated type of gastric carcinoma. Well-differentiated-type tumors, but not the poorly differentiated type, highly express VEGF, whose levels significantly correlate with vessel counts. bFGF expression was higher in the poorly differentiated type, especially scirrhous-type carcinoma. A majority of gastric carcinomas express IL-8/receptor systems, and the expression levels of IL-8 directly correlate with tumor vascularity [17]. Gastric carcinoma cells transfected with the IL-8 gene produce rapidly growing and highly vascular neoplasms at the orthotopic site (gastric wall) in nude mice [19]. Furthermore, IL-8 increases the expression of EGFR, VEGF, and IL-8 itself by the tumor cells themselves [20].

The microenvironment may influence the angiogenic phenotype of gastric carcinoma. In our in vitro study, *H. pylori* infection, a candidate promoter for gastric carcinoma, increased expression of mRNA encoding IL-8, VEGF, and angiogenin by tumor cells [21]. In addition to the neoplastic cells, various interstitial cells in the tumor microenvironment may be involved in angiogenesis. Macrophage infiltration into gastric carcinoma correlates significantly with tumor vascularity and monocyte chemoattractant protein (MCP)-1 expression by tumor cells. Because the activated macrophage is a producer for VEGF, IL-8, and PD-ECGF, MCP-1 expressed by gastric carcinoma cells plays a role in angiogenesis via macrophage recruitment and activation.

Molecular Bases of Gastric and Intestinal Phenotype Gastric Carcinoma

Well-differentiated gastric carcinoma is classified into those with gastric and intestinal phenotypes by mucin histochemistry and immunohistochemistry [22]. Gastric carcinoma cells can be differentiated into a gastric epithelial cell (G) type, resembling pyloric glands and foveolar epithelia, and an intestinal epithelial cell (I) type, such as goblet and intestinal absorpitive cells, by analyzing phenotypic expression. The *p53* gene abnormalities are frequently associated with I-type carcinoma, whereas LOH of the *p73* gene, a homologue of *p53*, occurs specifically in G type with foveolar epithe-

lial phenotype [23,24]. Caudal-type homeobox (*CDX*) 1 and *CDX2* are members of the caudal-related homeobox gene family, and CDX proteins act as intestine-specific transcription factors [25]. CDX2 upregulates goblet-specific *MUC2* gene expression [26]. I-type carcinomas express CDX1 and CDX2 at high levels [25]. Liver-intestine (LI) cadherin, also known as cadherin 17 (CDH17), is overexpressed in I-type carcinoma that is correlated with tumor invasion and metastasis [27–29]. It has been shown that CDX2 binds to the promoter of *CDH17* and upregulates gene expression [30]. On the other hand, the expression of SOX2, a member of transcription factor family containing an *Sry*-like high-mobility group box, is well preserved in G-type carcinoma and down-regulated in I-type carcinoma [22]. MSI associated with *hMLH1* hypermethylation is frequent in G-type carcinoma [23]. Details of the molecular bases of gastric carcinoma with foveolar epithelial phenotype are described in chapter by Yokozaki et al. (this volume).

Epigenetic Alterations of Tumor-Related Genes

DNA Methylation

Many lines of evidence indicate that DNA methylation is important in differential control of gene expression. The abnormal methylation of CpG islands associated with tumor suppressor genes can lead to transcriptional silencing, inactivating the gene and participating in tumorigenesis. In gastric carcinoma, aberrant methylation is involved in the inactivation of various important genes such as $p16^{MTS1/INK4A}$, *CDH1* (E-cadherin), *hMLH1*, *RAR-beta*, *RUNX3*, *MGMT* (O^6-methylguanine methyltransferase), *TSP1* (thrombospondin-1), *HLTF* (helicase-like transcription factor), *RIZ1* (retinoblastoma protein-interacting zinc finger gene-1), and *CHFR* [4,31–36]. The incidence of DNA hypermethylation and inactivation of these genes in gastric carcinoma ranges from 10% to 70%. The expression is restored by treatment of 5-aza-2′-deoxyxytidine (5-aza-dC), a DNA methyltransferase inhibitor. Because these genes have respective functions, the inactivation participates in stomach carcinogenesis through abnormalities in cell-cycle regulation, cell adhesion property, signal transduction, gene regulation, DNA repair, and so on. Carcinomas frequently have the CpG island methylator phenotype (CIMP) [37]. Gastric carcinomas showing methylation at more than three of the five loci of *methylated in tumors* (MINT) were designated as CIMP positive. Significant association is found between the CIMP-positive and promoter hypermethylation of *hMLH1*, *p16*, *CDH1*, and *RAR-beta*. By a genome scanning technique, methylation-sensitive representational difference analysis, Kaneda et al. [38] found that nine CpG islands (CGIs) in the 5′-regions of nine genes, *LOX*, *HRASLS*, *bA305P22.2.3*, *FLNc* (gamma-filamin/ABPL), *HAND1*, a homologue of *RIKEN 2210016F16*, *FLJ32130*, *PGAR* (*HFARP/ANGPTL4/ARP4*), and thrombomodulin, were methylated in gastric carcinoma cell lines but unmethylated in the normal samples. These genes may include important genes in gastric carcinoma development and would be useful to identify a distinct subset of gastric carcinomas.

Alterations in DNA methylation patterns sometimes differ depending on histological type of gastric carcinoma [39,40]. Hypermethylation of *hMLH1* is frequent in pap-

illary subtype (foveolar phenotype) of well-differentiated adenocarcinomas [23]. On the other hand, CpG island methylation of *CDH-1* and reduced E-cadherin expression is commonly observed in poorly differentiated adenocarcinoma of nonsolid (scirrhous) type [39]. Methylation of *CDH1* promoter is known as the second genetic hit in hereditary scirrhous gastric carcinoma. Furthermore, CIMP and *p16* methylation are frequent in well-differentiated type or poorly differentiated solid type, whereas *RAR-beta* methylation is common in the poorly differentiated nonsolid type [40].

In addition to tumor-specific DNA methylation, some gene promoters become hypermethylated in nonneoplastic condition during aging. Alternatively, the incidence of promoter hypermethylation of *hMLH1* and *p16* is more frequent in nonneoplastic gastric mucosa of gastric carcinoma patients than in those of noncancer individuals. Although hypermethylation of *hMLH1*, *p16*, *TSP1*, and *TIMP-3* sometimes occurs in intestinal metaplasia and adenomas, the number of methylated genes increases from normal mucosa to intestinal metaplasia to adenoma to carcinoma [41]. These observations indicate that DNA methylation occurs early and accumulates along the multistep stomach carcinogenesis.

Although DNA methyltransferase and demethylase are enzymes potentially affecting promoter methylation status, tumor-specific hypermethylation is not fully understood and does not simply depend on the expression levels of promethylating (DNMT1, DNMT3A, DNMT3B) and antimethylating (MBD2) enzymes. It has been shown that DNMT1 and DNMT3B cooperate to silence genes and that DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancers [42,43].

Histone Modification and Chromatin Remodeling

Histone acetylation and chromatin remodeling linked with CpG island methylation play a major role in the epigenetic regulation of gene expression [44]. Acetylation of histones through an imbalance of histone acetyltransferases and deacetylases disrupts nucleosome structure, which leads to DNA relaxation and a subsequent increase in accessibility for transcription factors. There is a tight association between histone acetylation and DNA methylation. Histone deacetylase-1 (HDAC1) can form a complex with both methyl-CpG-binding proteins (MeCP) and DNMT1 to silence the gene expression. In contrast, methylation of histone tails is alternately linked to activation and repression, depending on the residue methylated [45]. The expression of acetylated histone H4 is reduced in 70% of gastric carcinomas, 40% of gastric adenomas, and some of the intestinal metaplasia adjacent to carcinoma, suggesting that a low level of global histone acetylation may occur even in precancerous cells [5]. Furthermore, reduced histone acetylation is significantly associated with depth of tumor invasion and nodal metastasis of gastric carcinoma. Hypoacetylation of histones H3 and H4 in the $p21^{WAF1/Cip1}$ promoter region is observed in more than 50% of gastric cancer tissues by chromatin immunoprecipitation (ChIP). Hypoacetylation of histone H3 in the promoter is associated with reduced expression of p21 regardless of *p53* gene status. A HDAC inhibitor, trichostatin A (TSA), induces growth arrest and apoptosis and suppresses invasion of gastric carcinoma cells [5]. TSA increases the expression of p21, CBP, Bak, and cyclin E, while it reduces the

expression of E2F-1, E2F-4, HDAC-1, and the phosphorylated form of Rb protein [5]. TSA also induces the expression of many suppressor genes of invasion and metastasis including TIMPs and nm23H1/H2. These findings suggest that histone deacethylation may participate not only in tumorigenesis but also in invasion and metastasis through modifying a variety of gene expression. Therefore, histone acetylation should be a promising target for cancer therapy, especially against invasive and metastatic disease.

Histone hypoacetylation and DNA hypermethylation occur concordantly in transcriptional regulation of several genes. For instance, HLTF is a homologue to SWI/SNFs, which are ATP-dependent chromatin remodeling enzymes [34]. Half of gastric cancers show DNA methylation of *HLTF* gene, whereas no gastric mucosa from healthy subjects show the methylation. Loss of HLTF expression in gastric carcinoma cells is rectified by 5-aza-dC and TSA. The acetylation levels of histones H3 and H4 in the CpG island of the HLTF are inversely associated with DNA methylation status.

Genetic Polymorphism and Gastric Carcinoma Risk

Genetic polymorphism is an important determinant for the endogenous cause of cancer. Individual variations in cancer risk are associated with genetic polymorphisms (specific variant alleles of different genes) that are present in a significant proportion of the normal population. Gonzalez et al. [46] has described an overview of genetic susceptibility and gastric carcinoma risk. Genetic susceptibility must be crucial in various processes relevant to stomach carcinogenesis, including (1) mucosal protection against *H. pylori* infection or other carcinogens; (2) the inflammatory response that conditions the maintenance, severity, and outcome of the *H. pylori* infection; (3) the functioninig of carcinogen detoxification and antioxidant protection; (4) the intrinsic variability of DNA repair processes; and (5) cell proliferation activity. Representative reports of the association between genetic polymorphism and gastric carcinoma risk are shown in Table 4. IL-1beta gene (*IL1B*) and the IL-1 receptor ang-agonist gene (*IL1RN*) variants *IL1B* (-31 T genotype) and *IL1RN* IVS 86bp VNTR (2/2 genotype), thought to increase IL-1beta production and to inhibit gastric acid secretion, are associated with an increased risk of chronic hypochlorhydric response to *H. pylori* infection and an increased gastric carcinoma risk. *NAT1* is responsible for *N*-acetyltransferase activity, which catalyzes acetylation and modification of aromatic and heterocyclic amine carcinogens. A significant increase of gastric carcinoma risk is associated with genotypes of NAT1 (1088 T > A, 1095 C > A). In the Japanese population, gastric cancer risk is particularly high in well-differentiated carcinoma and in heavy smokers, suggesting the involvement of NAT1 in smoking-induced stomach carcinogenesis.

As to the relation between polymorphism of tumor-related genes and cancer risk, several studies have been performed. Single nucleotide polymorphism (SNP) (A > G, *Ile* > *Val*) is present in the transmembrane domain of the *HER-2*/c-*erb*B2. Our case-control study has demonstrated that the *Val* genotype is significantly more frequent in gastric carcinoma patients than in controls. In patients, gastric carcinomas of advanced stage are more frequent in patients with *Val* genotype than those with *Ile*

TABLE 4. Association of genetic polymorphism with gastric carcinoma risk and progression

Gene and molecule	Site of single nucleotide polymorphism (SNP)	Role	Reference
MUC1	Coding VNTR	Risk Portuguese	Carvalho F, Seruca R, David L, et al. (1997) Glycoconj J 14:107–111
Interleukin 1 beta (*IL1B*)	Promoter –31 C/T	Risk	El-Omar EM, Carrington M, Chow WH, et al. (2000) Nature (Lond) 404:398–402
Interleukin 1 receptor antagonist (*IL1RN*)	IVS2 86-bp VNTR	Risk	El-Omar EM, Carrington M, Chow WH, et al. (2000) Nature (Lond) 404:398–402
N-Acetyltransferase 1 [*NAT1*]	1088 T/A, 1095 C/A	Risk	Katoh T, Boissy RJ, Nagata N, et al. (2000) Int J Cancer 85:46–49
Cytochrome P450 2E1 (*CYP2E1*)	–1053 C/T	Risk Brazilians	Nishimoto IN, Hanaoka T, Sugimura H, et al. (2000) Cancer Epidemiol Biomark Prev 9:675–680
Glutathione *S*-transferase P1 (*GSTP1*)	Coding Ile105Val	Risk?	Katoh T, Kaneko S, Takasawa S, et al. (1999) Pharmacogenetics 9:165–169
Methylenetetrahydrofolate reductase (*MTHFR*)	Coding Ala677Val	Risk Chinese	Shen H, Xu Y, Zheng Y, et al. (2001) Int J Cancer 95:332–336
HER-2/*c-erb*B2	Coding Ile 665 Val	Risk	Kuraoka K, Oue M, Matsumura S, et al. (2003) Int J Cancer 107:593–596
MMP-1	Promoter –1607 G/GG	Histology	Matsumura S, Oue N, Kitadai Y, et al. (2004) J Cancer Res lin Oncol 130:259–265

genotype, suggesting that this SNP could modulate gastric cancer risk and serve as a predictor of risk for a malignant phenotype. Matrix metalloproteinase-1 (MMP-1) plays a key role in cancer invasion and metastasis. There is 1G/2G SNP in the promoter region of the *MMP-1* affecting the transcriptional activity. Although no difference has been found in the frequency of 1G/2G genotype between gastric carcinoma patients and controls, a significant association is detected with histological differentiation. The 2G genotype is more frequent in poorly differentiated gastric carcinoma than in well-differentiated tumors. Controversial observations have been reported in the association between *CDH1* (E-cadherin) promoter (−160 C > A) polymorphism and the risk of gastric carcinoma. One report indicates that individuals with A/A genotype have a decreased risk of gastric carcinoma [47], whereas another shows no difference in genotype frequencies between gastric carcinoma cases and controls [48]. The important limitations in case-control studies that preclude definitive conclusions are lack of appropriate control, low number of cases analyzed, and lack of concomitant analysis with exposure to relevant cofactors such as *H. pylori* infection and smoking. Proper association studies between genetic polymorphism and cancer risk and genotype information in individuals must be important because those factors directly connect with personalized cancer prevention. Furthermore, genetic polymorphisms have been associated with therapeutic efficacy and toxicity of anticancer drugs [49]. For instance, polymorphism of VNTR in the promoter region of thymidylate synthase influences response to 5-fluorouracil. Polymorphism (difference in number of TA repeats) in the promoter region of the UDP-glucuronosyltransferase 1A1 gene affects severity of toxicity during irinotecan (CPT-11) therapy.

Novel Genetic Markers Identified by Gene Expression Profile

Microarray Study

Cancer is accompanied by multiple genetic and epigenetic alterations, including mutation, gene amplification, LOH, gene silencing by DNA methylation, and loss of imprinting, all of which modify gene expression profiles. Therefore, genome-wide study of gene expression is greatly important to uncover the precise mechanism of development and progression of cancer. Microarray technology provides high-throughput analysis of gene expression profiles by means of small-array slides. cDNA microarray, array slides spotted with cDNAs, is commonly used to detect differences between tumor and normal cells among various histologies and clinical outcomes, for example. The use of laser capture microdissection and T7-based RNA amplification helps to study gene expression profile in a small amount of sample with minimal contamination of other components than those of interest.

Several microarray studies have been performed on gastric carcinoma. El-Rifai et al. [50] examined the gene expression profile of gastric carcinoma using cDNA microarray with 1200 genes and found that S100A4, CDK4, MMP14, and beta catenin are the most upregulated in gastric carcinoma. Hippo et al. [28] studied the expression profile of 6800 genes and identified 162 that were highly expressed in gastric carcinoma tissues; these included genes related to cell cycle, growth factor, cell motility,

cell adhesion, and matrix remodeling. They also found several genes associated with metastasis, including Oct-2, a POU domain transcription factor, or intestinal histology, including CDH17 and LI-cadherin. Hasegawa et al. [51] performed genome-wide analysis of gene expression in well-differentiated gastric cancer using a cDNA microarray representing 23040 genes and reported that 61 genes and 63 genes were commonly up-regulated and downregulated, respectively, in gastric carcinoma. Altered expression of 12 genes including *DDOST*, *GNS*, *NEDD8*, *LOC51096*, and *AIM2* was found to be associated with lymph node metastasis. Hasegawa et al. developed a "predictive score" based on the expression profiles of these five genes that could distinguish cancers with metastasis from those without metastasis. A similar approach has been carried out by Inoue et al. [52] to develop a prognostic scoring system using cDNA microarray. They selected 78 genes that were differentially expressed between aggressive and nonaggressive groups with respect to conventional pathological parameters and determined a coefficient for each gene. The prognostic score, calculated by summing up the value for each gene, could predict stage of disease and the patient's prognosis. Those strategies can be applicable to identify genes associated with sensitivity of cancer to anticancer drugs [53]. These observations indicate that the gene expression profile and a scoring system based on microarray analysis have great potential for dissecting the character of gene expression in individual cancers and predicting biological behavior and chemosensitivity.

Serial Analysis of Gene Expression (SAGE)

Besides microarray technique, serial analysis of gene expression (SAGE) is a powerful technique to allow global analysis of gene expression in a quantitative manner without prior knowledge of the sequence of the genes [54]. SAGE is based on the following principles. A short nucleotide sequence tag (about 10 base pairs) is sufficient to uniquely identify a transcript, provided it is isolated from a defined position within the transcript. Concentration of short sequence tags allows the efficient analysis of transcripts in a serial manner by the sequencing of multiple tags within a single clone. Because the SAGE tag numbers directly reflect the abundance of the mRNA, SAGE data are highly accurate and quantitative, and completion of the human genome sequence has facilitated the mapping of specific genes to individual tags. Up to now, four SAGE studies of gastric carcinoma, including ours, have been reported that identified several upregulated and downregulated genes [55–58]. Our SAGE study on five samples of gastric carcinoma of different stages and histology from four patients generated a total of 137706 tags including 38903 unique tags [58]. Our SAGE libraries are the largest gastric carcinoma libraries in the world, and sequence data from our SAGE libraries are publicly available at SAGEmap (GEO accession number GSE 545, SAGE Hiroshima gastric cancer tissue) (*http://www.ncbi.nlm.nih.gov/SAGE/*).

Comparison between SAGE tags from gastric carcinoma and those from normal gastric epithelia identifies upregulated and downregulated genes that may participate in stomach carcinogenesis (Table 5) [29,58]. If SAGE libraries are compared between early cancer and advanced cancer or between primary tumor and metastatic tumor, candidate genes involved in invasion and metastasis can be identified. The upregulated genes in gastric carcinoma include *APOC1*, *NDUF2*, *TEBP*, *COL1A1*, and so on, in addition to *TFF3* and *S100A4*, which are known to be upregulated in gastric carci-

noma [58]. Quantitative real-time reverse transcription-PCR (RT-PCR) confirmed that *APOC1*, *CEACAM6*, and *YF13H12* are frequently overexpressed. The downregulated gene cluster includes *LIPF* (gastric lipase), *CHIA*, *ATP4B*, *MBD3*, and many unknown genes. By comparing gene expression profiles between gastric carcinomas at early and advanced stages, several differentially expressed genes by tumor stage were also identified, including *FUS*, *CDH17*, *COL1A1*, and *COL1A2*, that should be novel genetic markers for high-grade malignancy. *FUS* is a tumor-associated fusion gene, especially in myxoid liposarcoma, and its possible role is supposed to be to regulate transcription and maintain chromosomal stability [59]. Regarding genes involved in metastasis, the 20 most upregulated tags and corresponding genes in the

TABLE 5. Upregulated and downregulated tags and genes in gastric carcinoma obtained by serial analysis of gene expression (SAGE)

Commonly upregulated and downregulated tags and genes in gastric carcinoma in comparison with normal gastric epithelia	
Upregulated	APOC1, S100A4, NDUF2, TEBP, COL1A2, SUFU, SYAP1, KIAA0930, KIAA1694, TFF3, CEACAM6, FLJ20249, FLJ2167, EIF4A1, COLPH2, G3BP, YF13H12, KRT7, SH3BP2, COL1A1, LOC284371
Downregulated	CAGCGCTTCT (no match), CACCTCCCCA (no match), AGCCTCCCCA (no match), ACCCTCCCCA (no match), LIPF, AACCTCCCCC (no match), CHIA, TAGTGCTTCT (no match), TACAAGGTCC (no match), GTGGTCAGCT (no match), ATP4B, FLJ20410, MBD3, CAGTGCTTTT (no match), Hs.199360, Hs.353061
The 20 most upregulated and downregulated tags and genes in advanced carcinoma in comparison with early carcinoma[a]	
Upregulated	TCCCCGTAAA (no match), TCCCGTACAT (no match), CDH17, FUS, PRO1073, FLJ36926, FLJ30146, PAI-RBP1, COL1A2, TCCTATTAAG (no match), COL1A1, GRAP2, HNRPL, NUTF2, ERP70, PES1, CYP2J2, DAG1, IQGAP1, IL16, FXYD3, COQ4, LOC91966, CTBP1, TTCGGTTGGT (no match), alpha4GnT, Hs.290723, AKT3, CCT3, HMG20A
Downregulated	Hs.216636, LOC116228, SH3MD2, NAB1, TTCCCCCAAA (no match), DDX5, VMP1, LOC51123, LZK1, CGCAGATCAG (no match), IFRD2, Hs.284464, RPS4Y, RPS4Y2, UAP1, Hs.180804, CATTAAATTA (no match), IKBKAP, ARPC3, NAGA, UBE3A, TRAG3, PNN, CTAATTCTTT (no match), TCCATCGTCC (no match)
The 20 most upregulated and downregulated tags and genes in metastatic tumor in comparison with primary tumor of gastric carcinoma[a]	
Upregulated	SCAND1, RGS5, S100A11, RNPC2, APOE, FLJ10815, RNASE1, H3F3B, P24B, LOC151103, CLDN3, MRPL14, PRex1, TCCCCTATTA (no match), Hs.105379, ATP5G1, NPD007, MGC3180, WDR11, ARPC1B, ABTB2, DNAJB1, HMGN2, KIAA1393, RAP1B, FLJ12150, STUB1
Downregulated	ERdj5, RPL27A, DHRS3, E2IG5, USP7, CTSL, KRTHB1, KRTHB3, TGCACTACCC (no match), ALG12, S100A9, CTAGCTTTTA (no match), ELOVL5, LOC375463, GGGGGAGTTT (no match), ACTGCCCTCA (no match), SPC18, CTNND1, CYP20A1, FLJ11151, RPS17, ZYX, RPS16, GCTTTCTCAC (no match), BCL2L2

Symbol of gene is described; UniGene ID is described if symbol is not present
No match, tag sequence is not matched to known gene
[a] Because some genes share the same SAGE tag, gene numbers are more than 20

metastatic tumor of gastric carcinoma included *SCAN D1*, *RGS5*, *S100A11*, *RNPC2*, and *APOE* [58]. *APOE* (apolipoprotein E) expression is associated with T grade, N grade, and advanced stage.

SAGE is also useful to isolate novel biomarkers of gastric carcinoma. The ideal biomarker should be overexpressed in a majority of gastric carcinoma and expressed on the cell surface or secreted to facilitate its detection. Moreover, if the function of the gene product is involved in the neoplastic process, the gene is not just a biomarker but can be a therapeutic target. One example is *REGIV* (regenerating gene type IV), which is identified by comparing the expressed tags of poorly differentiated nonsolid type (scirrhous-type) gastric carcinoma with those of normal gastric epithelia [58,60]. About half of gastric carcinomas overexpress *REGIV* mRNA regardless of tumor stage and histological differentiation. In vitro studies using *RegIV*-transfected cells revealed that RegIV is secreted by carcinoma cells and that RegIV inhibits apoptosis, suggesting that RegIV may serve as a novel biomarker and therapeutic target for gastric carcinoma. Other examples include *GW112* and *MIA*, both of which encode secreting proteins [61,62]. GW112 demonstrates strong antiapoptotic effects in cancer cells treated with stress exposures and forced expression of GW112 leads to more rapid tumor formation, indicating that GW112 plays an important role in tumor cell survival and growth and should be a good therapeutic target [61].

Clinical Implication of Global Gene Expression Analysis

A strategy to clinical applications of global analysis of gene expression such as diagnostics, treatment, and prevention is shown in Fig. 3. According to gene expression profiles among gastric carcinomas or with those in normal gastric tissue obtained by microarray study or SAGE, specifically upregulated or downregulated genes are identified. The expression of these genes is confirmed in a large number of cases by real-time RT-PCR and immunohistochemistry if antibodies are available. With the specific genes identified by SAGE, known genes participating in the development and progression of gastric carcinoma and known genetic markers for chemosensitivity, a custom-made cDNA microarray is prepared. If the specific gene encodes secretory protein, this may be detected in the blood and should be a novel biomarker of gastric carcinoma. For such molecules, DNA/RNA aptamer or antibody is produced to establish a measuring system such as enzyme-limited immunosorbent assay (ELISA) in blood sample. These methods can be applied for clinical diagnosis and cancer detection. Polymorphism of genes, highly altered in their expression in gastric carcinoma, may be candidates of novel risk factors, and this information will be used for cancer prevention. By functional analysis, the molecular mechanism of stomach carcinogenesis can be understood in more detail and the possibility whether the genes are novel therapeutic targets can be revealed. Combination of these testings not only can attain cancer detection but also can clarify the character of an individual tumor and person, which is directly connected with personalized medicine and cancer prevention.

Conclusion

In the course of multistep carcinogenesis of the stomach, various alterations of oncogenes, tumor suppressor genes, DNA repair genes, growth factors/receptors, cell-cycle

regulators, and cell adhesion molecules are accumulated. Some of these changes occur commonly in both well-differentiated and poorly differentiated types and some differ depending on the histological types. Among various epigenetic alterations, modified gene expression through DNA methylation and chromatin remodeling by histone modification are the most important events. Genetic polymorphism is a crucial endogenous cause and fundamental factor of cancer risk. Using genomic science including novel techniques for global analysis of gene expression and bioinformatics, the individual character of each person and cancer can be dissected precisely, which is directly connected to personalized medicine and cancer prevention. Understanding of the diversity of gastric cancer must be critical in the era of genomic medicine at the clinical setting.

References

1. Tahara E (1993) Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 119:265–272
2. Yasui W, Oue N, Kuniyasu H, et al (2001) Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 4:113–121
3. Ohgaki H, Yasui W, Yokota J (2003) Genetic pathway to human cancer. In: Vainio H, Hietanen E (eds) Handbook of experimental pharmacology. Mechanisms in carcinogenesis and cancer research. Springer, Heidelberg, pp 25–39
4. Yokozaki H, Yasui W, Tahara E (2001) Genetic and epigenetic changes in stomach cancer. Int Rev Cytol 204:49–95
5. Yasui W, Oue N, Ono S, et al (2003) Histone acetylation and gastrointestinal carcinogenesis. Ann NY Acad Sci 983:220–231
6. Todaro GJ, Huebner RJ (1972) N.A.S. symposium: new evidence as the basis for increased efforts in cancer research. Proc Natl Acad Sci U S A 69:1009–1015
7. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68:820–823
8. Nakasato F, Sakamoto H, Mori M, et al (1984) Amplification of the c-myc oncogene in human stomach cancers. Gann (Jpn J Cancer Res) 75:737–742
9. Sakamoto H, Mori M, Taira M, et al (1986) Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. Proc Natl Acad Sci U S A 83:3997–4001
10. Yasui W, Yokozaki H, Shimamoto F, et al (1999) Molecular-pathological diagnosis of gastrointestinal tissues and its contribution to cancer histopathology. Pathol Int 49:763–774
11. Kim NW, Piatyszek MA, Prowse KR, et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015
12. Yasui W, Tahara E, Tahara E, et al (1999) Immunohistochemical detection of human telomeraase reverse transcriptase in normal and precancerous lesions of the stomach. Jpn J Cancer Res 90:589–595
13. Kondo T, Oue N, Mitani Y, et al (2005) Loss of heterozygosity and histone hypoacetylation of the PINX1 gene are associated with reduced expression in gastric carcinoma. Oncogene 24:157–164
14. Kondo T, Oue N, Yoshida K, et al (2004) Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res 64:523–529
15. Fleisher AS, Esteller M, Wang S, et al (1999) Hypermethylation of the *hMLH1* promoter in human gastric cancers with microsatellite instability. Cancer Res 59:1090–1095
16. Takahashi Y, Cleary KR, Mai M, et al (1996) Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 2:1679–1684

17. Kitadai Y, Haruma K, Sumii K, et al (1998) Expression of IL-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 152:93–100
18. Takahashi Y, Bucana CD, Akagi Y, et al (1998) Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res 4:429–434
19. Kitadai Y, Takahashi Y, Haruma K, et al (1999) Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br J Cancer 81: 647–653
20. Kitadai Y, Haruma K, Mukaida N, et al (2000) Regulation of disease-progression genes in human gastric carcinoma cells by interleukin-8. Clin. Cancer Res 6:2735–2740
21. Kitadai Y, Sasaki A, Ito M, et al (2003) *Helicobacter pylori* infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells. Biochem Biophys Res Commun 311:809–814
22. Tatematsu M, Tsukamoto T, Inada K (2003) Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci 94:135–141
23. Ohmura K, Tamura G, Endoh Y, et al (2000) Microsatellite alterations in differentiated-type adenocarcinomas and precancerous lesions of the stomach with special reference to cellular phenotype. Hum Pathol 31:1031–1035
24. Yokozaki H, Shitara Y, Fujimoto J, et al (1999) Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. Int J Cancer 83:192–196
25. Almeida R, Silva E, Santos-Silva F, et al (2003) Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol 199:36–40
26. Yamamoto H, Bai YQ, Yuasa Y (2003) Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun 300:813–818
27. Grotzinger C, Kneifel J, Patschan D, et al (2001) LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut 49:73–81
28. Hippo Y, Taniguchi H, Tsutsumi S, et al (2002) Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 62:233–240
29. Yasui W, Oue N, Ito R, et al (2004) Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci 95:385–392
30. Hinoi T, Lucas PC, Kuick R, et al (2002) CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology 123: 1565–1577
31. Oshimo Y, Oue N, Mitani Y, et al (2004) Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 71:137–143
32. Oue N, Shigeishi H, Kuniyasu H, et al (2001) Promoter methylation of MGMT is associated with protein loss in gastric carcinomas. Int J Cancer 93:805–809
33. Oue N, Matsumura S, Nakayama H, et al (2003) Expression of theTSP-1 gene and its association with promoter hypermethylation in gastric carcinomas. Oncology 64:423–429
34. Hamai Y, Oue N, Mitani Y, et al (2003) DNA methylation and histone acetylation status of HLTF gene are associated with reduced expression in gastric carcinoma. Cancer Sci 94:692–698
35. Oshimo Y, Oue N, Mitani Y, et al (2004) Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int J Cancer 110:212–218
36. Satoh A, Toyota M, Itoh F, et al (2003) Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63:8606–8613
37. Toyota M, Ahuja N, Suzuki H, et al (1999) Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59:5438–5442
38. Kaneda A, Kaminishi M, Yanagihara K, et al (2002) Identification of silencing of nine genes in human gastric cancers. Cancer Res 62:6645–6650
39. Oue N, Motoshita J, Yokozaki H, et al (2002) Distinct promoter hypermethylation of p16ink4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinoma. J Pathol 198:55–59
40. Oue N, Oshimo Y, Mitani Y, et al (2003) DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci 94:901–905

41. Kang GH, Shim Y-H, Jung H-Y, et al (2001) CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 61:2847–2851
42. Rhee I, Bachman KE, Park BH, et al (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (Lond) 416:552–556
43. Robert M-F, Morin S, Beaulieu N, et al (2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33:61–65
44. Kouzarides T (1999) Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 9:40–48
45. Kouzarides T (2002) Histone methylation in transcriptional control. Curr Opin Genet Dev 12:198–209
46. Gonzalez CA, Sala N, Capella G (2002) Genetic susceptibility and gastric cancer risk. Int J Cancer 100:249–260
47. Wu M-S, Huang S-P, Chang Y-T, et al (2002) Association of the −160 C → A promoter polymorphism of the *E-cadherin* gene with gastric carcinoma risk. Cancer (Phila) 94:1443–1448
48. Pharoah PDP, Oliveira C, Machado JC, et al (2002) *CDH1* c-160a promoter polymorphism is not associated with risk of stomach cancer. Int J Cancer 101:196–197
49. Watters JW, McLeod HL (2003) Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 1603:99–111
50. El-Rifai W, Frierson HF Jr, Harper JC, et al (2001) Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer 92:832–838
51. Hasegawa S, Furukawa Y, Li M, et al (2002) Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23 040 genes. Cancer Res 62:7012–7017
52. Inoue H, Matsuyama A, Mimori K, et al (2002) Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res 8:3475–3479
53. Zembutsu H, Ohnishi Y, Tsunoda T, et al (2002) Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62:518–527
54. Velculescu VE, Zhang L, Vogelstein B, et al (1995) Serial analysis of gene expression. Science 270:484–487
55. El-Rafai W, Moskaluk CA, Abdrabbo MK, et al (2002) Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62:6823–6826
56. Oien KA, Vass JK, Downie I, et al (2003) Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. Oncogene 22:4287–4300
57. Lee J-Y, Eom E-M, Kim D-S, et al (2003) Analysis of gene expression profiles of gastric normal and cancer tissues by SAGE. Genomics 82:78–85
58. Oue N, Hamai Y, Mitani Y, et al (2004) Gene expression profile of gastric carcinoma; identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 64:2397–2405
59. Hicks GG, Singh N, Nashabi A, et al (2000) Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet 24:175–179
60. Hartupee JC, Zhang H, Bonaldo MF, et al (2001) Isolation and characterization of a cDNA encoding a novel member of the human generating protein family. Biochim Biophys Acta 1518:287–293
61. Zhang X, Huang Q, Yang Z, et al (2004) GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res 64:2474–2481
62. Krupnik VE, Sharp JD, Jiang C, et al (1999) Functional and structural diversity of the human Dickkopf gene family. Gene (Amst) 238:301–313

Color Plates to appear on the following pages.



FIG. 1. Multiple genetic and epigenetic alterations during stomach carcinogenesis. Words printed in *dark blue* represent genetic alterations and those in *green* represent epigenetic alterations



FIG. 2. Schematic illustration of cancer cells and macrophages in angiogenesis. *MCP-1*, monocyte chemoattractant protein-1; *IL*, interleukin; *TNF-α*, tumor necrosis factor-alpha; *VEGF*, vascular endothelial growth factor; *EGFR*, epidermal growth factor receptor; *PD-ECGF*, platelet-derived endothelial cell growth factor; *IL-8R*, IL-8 receptor



FIG. 3. Strategy to search for novel genes of gastric cancer through gene expression profiles and its clinical implication. *SAGE*, serial analysis of gene expression; *SNP*, single nucleotide polymorphism

Oncogene (2005), 1–12
© 2005 Nature Publishing Group All rights reserved 0950-9232/05 $30.00
www.nature.com/onc

ONCOGENOMICS

Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer

PP Aung[1], N Oue[1], Y Mitani[1], H Nakayama[1], K Yoshida[2], T Noguchi[3], AK Bosserhoff[4] and W Yasui[1]

[1]*Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan;* [2]*Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan;* [3]*Department of Oncological Science (Surgery II), Oita University Faculty of Medicine, Oita, Japan and* [4]*Institute of Pathology, University of Regensburg, Regensburg, Germany*

Gastric cancer (GC) is one of the most common malignancies worldwide. Genes expressed only in cancer tissue will be useful molecular markers for diagnosis and may also be good therapeutic targets. However, little is known about cancer-specific genes, at least in GC. In this study, we searched for GC-specific genes by serial analysis of gene expression (SAGE) data analysis and quantitative reverse transcription (RT)–PCR. Comparing GC SAGE libraries with those of various normal tissues in the SAGEmap database, we identified 54 candidate GC-specific genes. Quantitative RT–PCR analysis of these candidates revealed that *APin protein* (*APIN*), *taxol resistance-associated gene 3* (*TRAG3*), *cytochrome P450, family 2, subfamily W, polypeptide 1* (*CYP2W1*), *melanoma inhibitory activity* (*MIA*), *matrix metalloproteinase-10* (*MMP-10*), *dickkopf homolog 4* (*DKK4*), *GW112*, *regenerating islet-derived family, member 4* (*REGIV*), and *HORMA domain-containing 1* (*HORMAD1*) were expressed much more highly in GC than in 14 kinds of normal tissues. Immunohistochemical staining for MIA, MMP-10, and DKK4 was found in 47 (31.1%), 68 (45.0%), and two (1.3%) of 151 GCs, respectively, and staining for both MIA and MMP-10 was correlated with poor prognosis in advanced GC ($P = 0.0001$ and 0.0141, respectively). Moreover, enzyme-linked immunosorbent assay showed high levels of MMP-10 (65/69, 94.2%) in serum samples from patients with GC. Levels of MIA were raised in a small proportion of serum samples from patients with GC (4/69, 5.8%). In Boyden chamber invasion assays, MIA-transfected GC cells were up to three times more invasive than cells transfected with empty vector. Taken together, these results suggest that MMP-10 is a good marker for the detection of GC and that MIA and MMP-10 are prognostic factors for GC. As expression of MIA and MMP-10 is narrowly restricted in cancer, these two molecules may be good therapeutic targets for GC.

Oncogene advance online publication, 5 December 2005; doi:10.1038/sj.onc.1209279

Keywords: gastric cancer; MIA; MMP10; DKK4; SAGE; tumor serum marker

Introduction

According to the World Health Organization, gastric cancer (GC) is the fourth most common malignancy worldwide, with approximately 870 000 new cases occurring yearly. Mortality due to GC is second only to that due to lung cancer (Ohgaki and Matsukura, 2003). Cancer develops as a result of multiple genetic and epigenetic alterations (Yasui *et al.*, 2000; Ushijima and Sasako, 2004). Better knowledge of changes in gene expression that occur during gastric carcinogenesis may lead to improvements in diagnosis, treatment, and prevention. Identification of novel biomarkers for cancer diagnosis and novel targets for treatment is a major goal in this field (Yasui *et al.*, 2004). Genes encoding transmembrane/secretory proteins expressed specifically in cancers may be ideal biomarkers for cancer diagnosis (Buckhaults *et al.*, 2001). If the function of the gene product is involved in the neoplastic process, this gene may constitute a therapeutic target.

We previously performed serial analysis of gene expression (SAGE) on four primary GC samples (Gene Expression Omnibus accession number GSE 545; SAGE Hiroshima GC tissue) and identified several genes and tags that are potentially involved in invasion, metastasis, and carcinogenesis (Oue *et al.*, 2004; Yasui *et al.*, 2004). In this study, to identify potential molecular markers for diagnosis of GC and molecular therapeutic targets, we systematically searched for GC-specific genes in SAGE libraries. Comparing GC SAGE libraries with those of various normal tissues in the SAGEmap

Correspondence: Dr W Yasui, Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
E-mail: wyasui@hiroshima-u.ac.jp
Received 28 June 2005; revised 12 September 2005; accepted 25 October 2005

database (Lal *et al.*, 1999), we identified 54 candidate GC-specific genes in GC libraries but not in libraries from 14 normal tissues, including brain, lung, and heart. We also performed quantitative reverse transcription (RT)–PCR to investigate the specificity of these candidate GC-specific genes. We show that *APin protein* (*APIN*), *taxol resistance-associated gene 3* (*TRAG3*), *cytochrome P450, family 2, subfamily W, polypeptide 1* (*CYP2W1*), *melanoma inhibitory activity* (*MIA*), *matrix metalloproteinase-10* (*MMP-10*), *dickkopf homolog 4* (*DKK4*), *GW112*, *regenerating islet-derived family, member 4* (*REGIV*), and *HORMA domain-containing 1* (*HORMAD1*) were much more highly expressed in GC than in normal tissues. Among these genes, overexpression of *REGIV* and *GW112* in GC has been reported (Oue *et al.*, 2004, 2005; Zhang *et al.*, 2004). Immunohistochemical analysis of MIA, MMP-10, and DKK4 in 151 GC samples revealed that MIA and MMP-10 are frequently overexpressed in GC. We also measured MIA and MMP-10 in serum and peritoneal wash fluid from patients with GC to investigate the potential utility of these measurements in cancer diagnosis.

Results

Identification of genes expressed more highly in GC than in normal tissues
To identify genes expressed specifically in GC, we compared tags from each GC SAGE library to the normal SAGE libraries (white matter, cerebellum, thalamus, heart, lung, stomach, colon, liver, kidney, leukocyte, peritoneum, skeletal muscle, spinal cord, and lymph node) as described in Materials and methods. We obtained 24 candidates from W226T, 15 candidates from W246T, 27 candidates from S219T, and 13 candidates from P208T. In total, we identified 54 individual candidate genes in our GC libraries but not in the normal libraries (Table 1). To confirm that these candidates were GC-specific, quantitative RT–PCR was performed to measure the expression of these candidates in nine GC samples and in 14 normal tissues (heart, lung, stomach, small intestine, colon, liver, pancreas, kidney, bone marrow, peripheral leukocytes, spleen, skeletal muscle, brain, and spinal cord). Representative results are shown in Figure 1. Expression of the 54 candidate genes was not necessarily specific for GC. However, several genes showed much higher expression in GC than in normal tissues. We then focused on cancer specificity. We calculated the specificity index for each gene. First, we identified the normal tissue in which the target gene expression was highest (mRNA expression levels are shown as A, Table 1). We then identified the GC among nine in which the target gene expression was highest (mRNA expression levels are shown as B, Table 1). The specificity index (B/A ratio) for each gene is shown in Table 1. Of the 54 candidates, nine genes: *APIN*, *TRAG3*, *CYP2W1*, *MIA*, *MMP-10*, *DKK4*, *GW112*, *REGIV*, and *HORMAD1* were found to show high specificity for GC.

mRNA expression of high-specificity genes for GC
Expression of the nine high-specificity genes for GC was analysed by quantitative RT–PCR in an additional 44 GC samples and corresponding non-neoplastic mucosa samples. We calculated the ratio of target gene mRNA expression levels between GC tissue (T) and corresponding non-neoplastic mucosa (N). T/N ratios >2-fold were considered to represent overexpression. Genes showing overexpression in >40% of the samples included *GW112* (25/44, 56.8%), *MMP-10* (23/44, 52.3%), *CYP2W1* (22/44, 50.0%), *HORMAD1* (20/44, 45.5%), and *TRAG3* (18/44, 40.9%). Other genes were overexpressed in <30% of the samples examined (*MIA*, 13/44, 29.5%; *APIN*, 12/44, 27.3%; *DKK4*, 11/44, 25.0%). mRNA expression levels of *GW112* were correlated with T grade (depth of tumor invasion, $P<0.0001$), N grade (degree of lymph node metastasis, $P=0.0089$), and tumor stage ($P=0.0019$; Table 2). Those of *MIA* were also correlated with T grade ($P=0.0007$), N grade ($P=0.0335$), and tumor stage ($P=0.0068$; Table 2).

Immunohistochemical staining for MIA, MMP-10, and DKK4 in GC and noncancerous tissues
To confirm overexpression of genes whose expression by RT–PCR was much higher in GC than in normal tissues, we performed immunohistochemical analysis of MIA, MMP-10, and DKK4 because antibodies against these three proteins are available. Immunohistochemical analysis was performed in noncancerous tissues with the highest mRNA expression to serve as positive controls. Immunostaining of MIA and MMP-10 in the lung, in which mRNA expression of both 2 genes was the highest, showed staining of chondrocytes in peribronchial cartilage, but not of epithelial components (Figure 2a, b). Both MIA and MMP-10 are reported to be expressed in cartilage (Dietz and Sandell, 1996; Kevorkian *et al.*, 2004). Little is known about DKK4 expression. *DKK4* mRNA is reported to be undetectable in all human adult and fetal tissues examined by Northern blotting (Krupnik *et al.*, 1999). As our quantitative RT–PCR showed the highest expression of *DKK4* in the duodenum, immunostaining for DKK4 was performed in the duodenum, and staining for DKK4 was observed in a small number of epithelial cells (Figure 2c). Staining was absent with antibody preincubated with DKK4 protein (data not shown).

Immunohistochemistry was then performed on 151 GC samples (Figure 2d–f). Of these, 47 (31.1%) were positive for MIA staining, 68 (45.0%) were positive for MMP-10 staining, and two (1.3%) were positive for DKK4 staining. We analysed the relation between staining for each of these three proteins and clinicopathologic characteristics. Staining for MIA was correlated with T grade ($P=0.0002$), N grade ($P=0.0015$), and tumor stage ($P<0.0001$) (Supplementary Table 1). Staining for MMP-10 was correlated with T grade ($P=0.0306$) (Supplementary Table 2). There was no clear correlation between DKK4 staining and clinical characteristics (data not shown). We also analysed the

Table 1 Summary of quantitative RT–PCR analysis of candidate genes specifically expressed in gastric cancer

Gene name	*Normal organ with highest expression*		*GC with highest expression*	*Specificity index (B/A)*	*GC case no. with two-fold mRNA expression over that of normal organ with highest expression*	*GC case no. with 10-fold mRNA expression over that of normal organ with highest expression*
	Organ name	*mRNA expression level (A)*	*mRNA expression level (B)*			
High specificity						
APIN	Stomach	1.0[a]	202.3[a]	202.3	3	1
TRAG3	Spleen	27.3	1038.3	38.1	4	3
CYP2W1	Small intestine	17.4	604.7	34.8	3	2
MIA	Lung	1.0	29.7	29.7	3	1
MMP10	Lung	3.1	63.6	20.8	10	2
DKK4	Small intestine	4.6	89.9	19.6	3	1
GW112	Small intestine	8.7	147	16.9	2	2
REGIV	Pancreas	8.9	112.2	12.6	1	1
HORMAD1	Leukocyte	43.7	448.8	10.3	2	1
Low specificity						
PPARBP	Brain	5.7	52.7	9.3	1	
SULT1C1	Kidney	1.1	6	5.5	3	
BIRC5	Bone marrow	2.7	13.5	4.9	3	
FLJ10036	Pancreas	1.8	6.2	3.4	5	
SH3BGRL2	Brain	4.5	12	2.7	1	
FLJ36666	Pancreas	3.5	7.8	2.2	2	
No specificity						
ETS2	Skeletal muscle	6.5	12.5	1.9		
TD-60	Pancreas	1.9	3.3	1.7		
MGC20806	Brain	4.2	6.1	1.5		
MYBL2	Bone marrow	3.5	4.4	1.3		
alpha4GnT	Pancreas	1.2	1.4	1.2		
GPP34R	Pancreas	12.6	12.7	1		
MLL4	Pancreas	4.9	4.6	0.9		
AQR	Pancreas	5.6	5	0.9		
TAPBP	Leukocyte	4.8	4.2	0.9		
KIF4A	Bone marrow	5	4.2	0.8		
ALDH7A1	Liver	1.1	0.8	0.7		
MAPK13	Pancreas	7.9	5.5	0.7		
FXYD3	Colon	4.3	2.8	0.6		
THBS3	Pancreas	6.2	3.5	0.6		
CCT3	Pancreas	10.6	5.4	0.5		
STAT2	Liver	5.2	2.7	0.5		
LMO6	Skeletal muscle	32.0	14.7	0.5		
TMLHE	Heart	21.4	9.4	0.4		
SFRS9	Pancreas	7.4	2.7	0.4		
C4orf9	Skeletal muscle	8.5	3	0.4		
SEC31L2	Skeletal muscle	13.1	4.6	0.3		
TYRO3	Brain	25.3	8.7	0.3		
HOXA10	Skeletal muscle	6472	1937.5	0.3		
JUN	Skeletal muscle	12.9	3.7	0.3		
ATPIF1	Heart	28.4	7.4	0.3		
ATE1	Heart	11.9	2.8	0.2		
BRD4	Skeletal muscle	11.8	2.7	0.2		
PEGASUS	Heart	9.6	2.1	0.2		
IL16	Brain	9.6	2.1	0.2		
TPT1	Pancreas	17.8	3.6	0.2		
PRKAG1	Skeletal muscle	13	2.6	0.2		
RPL8	Pancreas	11.6	2.2	0.2		
GITA	Heart	31.8	4.7	0.1		
NEK9	Heart	15	2.1	0.1		
IFRD1	Pancreas	20.8	2.4	0.1		
NIPSNAP3B	Skeletal muscle	49.5	5.6	0.1		
CBFA2T3	Pancreas	34.1	1.7	0.1		
DEFA6	Small intestine	108.4	1.7	0		
DEFA5	Small intestine	280.1	3.5	0		

[a]The units are arbitrary. Target mRNA expression levels were standardized to 1.0 μg total RNA from normal stomach as 1.0.



Figure 1 Quantitative RT–PCR analysis of candidate cancer (at least GC)-specific genes in 14 normal tissues and nine GC samples. Definitions of high specificity, low specificity, and no specificity are as described in Materials and methods. mRNA expression levels of *MIA*, *MMP-10*, and *DKK4* were much higher in GC samples than in normal tissues. In contrast, mRNA expression levels of *MAPK13*, *JUN*, and *IL16* were not significantly different between GC and normal tissues.

prognostic value of MIA and MMP-10 staining. The prognosis of patients with MIA- or MMP-10-positive tumors was significantly worse in the group of 58 advanced GC (invading through the muscularis propria into the serosa) patients ($P = 0.0001$ and 0.0141, respectively, log-rank test) (Figure 2g). In corresponding non-neoplastic gastric mucosa from GC patients, staining for MIA and MMP-10 was weak or negative, whereas DKK4-positive cells were detected in intestinal metaplasia of the stomach (data not shown).

MIA and MMP-10 levels in serum and peritoneal wash fluid from patients with GC

MIA and MMP-10 are reported to be secreted (Blesch *et al.*, 1994; Ramos *et al.*, 2004). Therefore, we

Table 2 Relation between mRNA expression and clinicopathologic characteristics in gastric cancer

Gene name	*TNM stage*	*mRNA expression*		P-*value*[b]
		Overexpression[a]	*Not over-expression*	
GW112	T grade			
	T1/2	5 (23.8%)	16	<0.0001
	T3/4	20 (87.0%)	3	
	N grade			
	N0	4 (26.7%)	11	0.0089
	N1/2/3	21 (72.4%)	8	
	Stage			
	Stage I/II	7 (31.8%)	15	0.0019
	Stage III/IV	18 (81.8%)	4	
	Histologic type			
	Intestinal	13 (54.4%)	11	0.7662
	Diffuse	12 (60.0%)	8	
MIA	T grade			
	T1/2	1 (4.8%)	20	0.0007
	T3/4	12 (52.2%)	11	
	N grade			
	N0	1 (6.7%)	14	0.0335
	N1/2/3	12 (41.4%)	17	
	Stage			
	Stage I/II	2 (9.1%)	20	0.0068
	Stage III/IV	11 (50.0%)	11	
	Histologic type			
	Intestinal	7 (29.2%)	17	1.0000
	Diffuse	6 (30.0%)	14	

[a]We calculated the ratio of target gene mRNA expression levels between GC tissue (T) and corresponding non-neoplastic mucosa (N). T/N ratios >2-fold were considered to represent overexpression. [b]Fisher's exact test.

determined whether these proteins can be detected in sera from patients with GC by enzyme-linked immunosorbent assay (ELISA). Among the 151 GC cases analysed by immunohistochemistry, serum samples were available for ELISA from 69 GC cases. MIA is known to be a tumor marker to detect metastatic disease in patients with malignant melanomas (Bosserhoff *et al.*, 1997), but MIA levels in serum from patients with GC have not been investigated. MIA levels were significantly higher in four of 17 serum samples from patients with stage IV GC than in those of healthy individuals (Figure 3a). MIA serum levels were not significantly different between patients with stage I, II, or III GC and healthy individuals. Of 20 serum samples from patients with gastritis, one showed a high MIA level. But, levels of MIA in all 20 serum samples were below 15 ng/ml. When the cutoff level for MIA was set at 20 ng/ml, the sensitivity for detection of GC was only 5.8% (4/69), but specificity was 100.0% (60/60). We compared the protein expression status obtained by immunostaining with serum levels of the MIA measured by ELISA in 69 GC cases. Levels of MIA in serum samples from the patients with GC showing MIA-positive immunostaining ($n=29$, mean±s.e. 7.7±2.1 ng/ml) did not differ significantly from those with GC showing MIA-negative immunostaining ($n=40$, 4.1±0.3 ng/ml) ($P=0.7656$, Mann–Whitney *U*-test). We also measured MIA levels in peritoneal wash fluid from patients with GC (Figure 3a). Of two peritoneal wash cytology-positive samples, one showed a very high MIA level.

To our knowledge, although some MMPs are good serum markers for cancer detection (Zucker *et al.*, 1999), there are no reports regarding MMP-10 levels in serum from patients with cancer including GC. MMP-10 was also detected in serum samples. In contrast to levels of the MIA, high levels of MMP-10 were detected in serum samples from most of the patients with GC (mean±s.e.; stage I, 455.8±38.1 pg/ml; stage II, 526.5±68.5 pg/ml; stage III, 574.1±61.1 pg/ml; stage IV, 546.0±51.0 pg/ml), even at stage I (Figure 3b). Levels of MMP-10 in serum samples from the patients with GC showing MMP-10-positive immunostaining ($n=34$, 553.0±38.3 pg/ml) were higher than those with GC showing MMP-10-negative immunostaining ($n=35$, 451.0±33.7 pg/ml), but not statistically significant ($P=0.1770$, Mann–Whitney *U*-test). High levels of MMP-10 were also detected in serum samples from some healthy individuals (81.4±25.5 pg/ml) and some patients with gastritis (47.8±23.0 pg/ml). When the cutoff level for MMP-10 was set at 200 pg/ml, the sensitivity and specificity for detection of GC was 94.2% (65/69) and 85.0% (51/60), respectively. Sensitivity for patients with stage II–IV GC was 100%. Levels of MMP-10 in all 27 peritoneal wash cytology-negative samples were below 50 pg/ml (Figure 3b). Two peritoneal wash cytology-positive samples showed levels of MMP-10 that were significantly higher than those in peritoneal wash cytology-negative samples.

Effect of MIA on cell growth and invasive activity of MKN-28 cells

High levels of MIA mRNA expression were correlated with T grade, N grade, and tumor stage in GC tissues. In addition, immunostaining for MIA protein was correlated with T grade, N grade, tumor stage, and poor prognosis. MIA acts as a potent tumor cell growth inhibitor for malignant melanoma cells (Blesch *et al.*, 1994) but not for pancreatic cancer cells (El Fitori *et al.*, 2005), whereas overexpression of MIA enhances the invasiveness of both melanoma cells and pancreatic cancer cells (Bosserhoff *et al.*, 2001; El Fitori *et al.*, 2005). To investigate the biologic significance of MIA in GC, the MKN-28 GC cell line was stably transfected with vector expressing MIA. MKN-28 cells were selected for low MIA expression (data not shown). Cells were transfected with plasmid vectors capable of expressing MIA constitutively. Clones were selected in G418 and examined for MIA expression by MIA ELISA (Figure 4a). Clones that expressed MIA at significantly increased levels relative to the parent are designated as MKN-28-1, MKN-28-2, and MKN-28-3. To determine the effect of MIA on cell growth, MTT assays were performed. Cell growth of MKN-28 cells expressing higher levels of MIA did not differ from that of cells transfected with empty vector up to days 2 (Figure 4b). We then performed Boyden chamber



Figure 2 Immunohistochemical analysis of MIA, MMP-10, and DKK4 in noncancerous tissue and GC tissue. Staining for MIA (**a**) and MMP-10 (**b**) was found in peribronchial cartilage of the lung. DKK4 staining (**c**) was detected in a small number of epithelial cells in the duodenum. In GC samples, staining for MIA (**d**), MMP-10 (**e**), and DKK4 (**f**) was found in GC cells. Original magnifications, **a**, **b**, and **d–f**, ×400; **c**, ×200. (**g**) Prognostic value of MIA and MMP-10 staining. The prognosis of patients with MIA- or MMP-10-positive tumors was significantly worse in the group of 58 advanced GC patients ($P = 0.0001$ and 0.0141, respectively, log-rank test).

invasion assays. MIA-transfected MKN-28 cells were up to three times more invasive than cells transfected with empty vector on day 2 (MKN-28-1, $P = 0.014$; MKN-28-2, $P = 0.046$; MKN-28-3, $P = 0.025$) (Figure 4c).

Discussion

Several tumor (breast cancer, lung cancer, and renal cell cancer)-specific genes have been identified by a combination of subtractive hybridization and cDNA microarray technology (Amatschek *et al*., 2004). In this study, we searched for GC-specific genes by SAGE data analysis and quantitative RT–PCR. True cancer-specific genes were not found, but *APIN*, *TRAG3*, *CYP2W1*, *MIA*, *MMP-10*, *DKK4*, *GW112*, *REGIV*, and *HORMAD1* were expressed much more highly in GC than in 14 types of normal tissues. As these genes were identified by SAGE and quantitative RT–PCR analysis of bulk GC tissues, immunohistochemistry was required to determine which cells expressed these genes. Antibodies against MIA, MMP-10, and DKK4 were available, and staining for all three proteins was confirmed in GC cells. But, DKK4 expression was present in only two out of 151 GC cases and generally absent.

MIA was first isolated as an 11-kDa protein secreted by malignant melanoma cell lines (Blesch *et al*., 1994). MIA is a potent inhibitor of proliferation of malignant melanoma cells and other neuroectodermal tumor cells (Blesch *et al*., 1994). Overexpression of MIA has been reported in breast cancer (Bosserhoff *et al*., 1999),